North American Spine Society journal

Do drugs that activate GLP-1 receptors affect healing after neck bone fusion? A review and combined analysis

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with obesity and type 2 diabetes.

  • The procedure-specific effects of GLP-1RAs in cervical fusion are not well understood.
  • Use of GLP-1RAs may influence outcomes in surgical procedures.
  • There is a growing interest in the impact of GLP-1RAs on various medical conditions.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Aug '26
Effects of diabetes drugs on recovery after neck spine surgery
top 20% journal
journal article
Jan '26
Use of GLP-1 Receptor Drugs and Surgery Outcomes After Neck Spine Fusion
top 5% journal
cited by 1 paper
journal article
Aug '26
GLP-1 receptor agonists and recovery results after neck spine fusion surgery: a review and analysis of real-world data
top 20% journal
journal article
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Feb '26
Use of Glucagon-Like Peptide-1 Therapy Around Surgery and Recovery Results in Adult Foot and Ankle Operations
cited by 1 paper
journal article
Jan '26
Do GLP-1 drugs change surgery risks in spine operations? A review and combined analysis
top 20% journal
journal article
Jul '26
Possible effects of glucagon-like peptide-1 receptor drugs on recovery after spine surgery
top 20% journal
Oct '21
Comparing diabetes drugs for people with heart disease: a network analysis of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors
cited by 44 papers
systematic review
Dec '25
GLP-1 Receptor Agonists and the Risk of Needing Repeat Surgery After Neck Spine Fusion
top 30% journal
cited by 3 papers
journal article
Jun '26
Lung-related side effects linked to GLP-1 receptor agonist medications: a review of respiratory safety concerns
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief